Literature DB >> 25979947

Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.

Fabienne McClanahan1, John C Riches2, Shaun Miller2, William P Day2, Eleni Kotsiou2, Donna Neuberg3, Carlo M Croce4, Melania Capasso5, John G Gribben2.   

Abstract

T-cell defects, immune suppression, and poor antitumor immune responses are hallmarks of chronic lymphocytic leukemia (CLL), and PD-1/PD-L1 inhibitory signaling has emerged as a major immunosuppressive mechanism. However, the effect of different microenvironments and the confounding influence of aging are poorly understood. The current study uses the Eμ-TCL1 mouse model, which replicates human T-cell defects, as a preclinical platform to longitudinally examine patterns of T-cell dysfunction alongside developing CLL and in different microenvironments, with a focus on PD-1/PD-L1 interactions. The development of CLL was significantly associated with changes in T-cell phenotype across all organs and function. Although partly mirrored in aging wild-type mice, CLL-specific T-cell changes were identified. Murine CLL cells highly expressed PD-L1 and PD-L2 in all organs, with high PD-L1 expression in the spleen. CD3(+)CD8(+) T cells from leukemic and aging healthy mice highly expressed PD-1, identifying aging as a confounder, but adoptive transfer experiments demonstrated CLL-specific PD-1 induction. Direct comparisons of PD-1 expression and function between aging CLL mice and controls identified PD-1(+) T cells in CLL as a heterogeneous population with variable effector function. This is highly relevant for therapeutic targeting of CD8(+) T cells, showing the potential of reprogramming and selective subset expansion to restore antitumor immunity.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25979947      PMCID: PMC4497962          DOI: 10.1182/blood-2015-02-626754

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  56 in total

1.  A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease.

Authors:  Davide Bagnara; Matthew S Kaufman; Carlo Calissano; Sonia Marsilio; Piers E M Patten; Rita Simone; Philip Chum; Xiao-Jie Yan; Steven L Allen; Jonathan E Kolitz; Sivasubramanian Baskar; Christoph Rader; Hakan Mellstedt; Hodjattallah Rabbani; Annette Lee; Peter K Gregersen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

2.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.

Authors:  Christian Steidl; Sohrab P Shah; Bruce W Woolcock; Lixin Rui; Masahiro Kawahara; Pedro Farinha; Nathalie A Johnson; Yongjun Zhao; Adele Telenius; Susana Ben Neriah; Andrew McPherson; Barbara Meissner; Ujunwa C Okoye; Arjan Diepstra; Anke van den Berg; Mark Sun; Gillian Leung; Steven J Jones; Joseph M Connors; David G Huntsman; Kerry J Savage; Lisa M Rimsza; Douglas E Horsman; Louis M Staudt; Ulrich Steidl; Marco A Marra; Randy D Gascoyne
Journal:  Nature       Date:  2011-03-02       Impact factor: 49.962

Review 3.  T cell exhaustion.

Authors:  E John Wherry
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

4.  Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

Authors:  Seng-Ryong Woo; Meghan E Turnis; Monica V Goldberg; Jaishree Bankoti; Mark Selby; Christopher J Nirschl; Matthew L Bettini; David M Gravano; Peter Vogel; Chih Long Liu; Stephanie Tangsombatvisit; Joseph F Grosso; George Netto; Matthew P Smeltzer; Alcides Chaux; Paul J Utz; Creg J Workman; Drew M Pardoll; Alan J Korman; Charles G Drake; Dario A A Vignali
Journal:  Cancer Res       Date:  2011-12-20       Impact factor: 12.701

5.  Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL.

Authors:  J Piñón Hofbauer; C Heyder; U Denk; T Kocher; C Holler; D Trapin; D Asslaber; I Tinhofer; R Greil; A Egle
Journal:  Leukemia       Date:  2011-05-24       Impact factor: 11.528

6.  Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.

Authors:  Claudia Nunes; Ryan Wong; Malcolm Mason; Chris Fegan; Stephen Man; Chris Pepper
Journal:  Clin Cancer Res       Date:  2011-12-21       Impact factor: 12.531

7.  Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults.

Authors:  Jaikumar Duraiswamy; Chris C Ibegbu; David Masopust; Joseph D Miller; Koichi Araki; Gregory H Doho; Pramila Tata; Satish Gupta; Michael J Zilliox; Helder I Nakaya; Bali Pulendran; W Nicholas Haining; Gordon J Freeman; Rafi Ahmed
Journal:  J Immunol       Date:  2011-03-07       Impact factor: 5.422

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

9.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

10.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

View more
  59 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

2.  PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.

Authors:  Bola S Hanna; Philipp M Roessner; Annika Scheffold; Billy M C Jebaraj; Yasmin Demerdash; Selcen Öztürk; Peter Lichter; Stephan Stilgenbauer; Martina Seiffert
Journal:  Leukemia       Date:  2018-12-20       Impact factor: 11.528

3.  Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

Authors:  A Vardi; E Vlachonikola; M Karypidou; E Stalika; V Bikos; K Gemenetzi; C Maramis; A Siorenta; A Anagnostopoulos; S Pospisilova; N Maglaveras; I Chouvarda; K Stamatopoulos; A Hadzidimitriou
Journal:  Leukemia       Date:  2016-11-25       Impact factor: 11.528

4.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

Review 5.  Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia.

Authors:  Noelia Purroy; Catherine J Wu
Journal:  Cold Spring Harb Perspect Med       Date:  2017-04-03       Impact factor: 6.915

6.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

7.  NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.

Authors:  Timothy L Chen; Minh Tran; Aparna Lakshmanan; Bonnie K Harrington; Nikhil Gupta; Virginia M Goettl; Amy M Lehman; Stephen Trudeau; David M Lucas; Amy J Johnson; John C Byrd; Erin Hertlein
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

8.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

9.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 10.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.